Financials in USD. Standardized financial statements.
A compact view of how Onconetix, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $815,371 | $2.52M | $58,465 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -67.7% | +4217.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $182,458 | $1.47M | $1.19M | $6,752 | $4,890 | $3,056 | $573 |
| Gross Profit? | $632,913 | $1.06M | -$1.13M | -$6,752 | -$4,890 | -$3,056 | -$573 |
| Gross Margin? | +77.6% | +41.8% | -1927.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $6.98M | $57.54M | $34.91M | $13.48M | $3.42M | $1.62M | $879,659 |
| Operating Income? | -$6.34M | -$56.49M | -$36.03M | -$13.48M | -$3.42M | -$1.62M | -$880,230 |
| EBITDA? | -$13.27M | -$57.60M | -$36.71M | -$13.41M | -$3.41M | -$1.60M | -$821,342 |
| Income Before Tax | -$14.03M | -$59.74M | -$37.42M | -$13.42M | -$3.42M | -$1.60M | -$821,915 |
| Income Tax Expense | $525 | -$1.05M | -$12,593 | $0 | $0 | $0 | $0 |
| Net Income? | -$14.03M | -$58.69M | -$37.41M | -$13.42M | -$3.42M | -$1.60M | -$821,915 |
| EPS? | $-4.73 | $-520.93 | $-25.03 | $-0.31 | $-0.09 | $-0.04 | $-0.02 |
| Diluted EPS? | $-4.73 | $-520.93 | $-25.03 | $-0.31 | $-0.09 | $-0.04 | $-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality